What's new? Log in Free sign up

Novo Nordisk A/S (NVO)

Company Profile

Company profile

Ticker

NVO, NONOF

Exchange

Website

www.novonordisk.com

CEO

Mr. Lars Fruergaard Jorgensen

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • AbbVie • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Bausch Health Companies • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

BEXY COMMUNICATIONS INC, CHENIERE ENERGY INC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

NVO stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Disclosure regarding Iran Threat Reduction and Syria Human Rights Act

Current report (foreign)

Current report (foreign)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

BlackRock, Inc.

Annual report of employee stock purchases

Annual report of employee stock purchases

Annual report of employee stock purchases

Annual report of employee stock purchases

Annual report of employee stock purchases

Annual report of employee stock purchases

Financial summary

Financial statements Chart NVO financial data

Quarter (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q4 2024

NVO institutional ownership history Ownership history

7.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1643	1774	-7.4%
Opened positions	202	150	+34.7%
Closed positions	333	226	+47.3%
Increased positions	587	694	-15.4%
Reduced positions	637	641	-0.6%

13F shares	Current	Prev Q	Change
Total value	26.46 tn	36.09 tn	-26.7%
Total shares	337.28 mm	334.59 mm	+0.8%
Total puts	10.51 mm	7.78 mm	+35.2%
Total calls	11.35 mm	4.94 mm	+129.9%
Total put/call ratio	0.9	1.6	-41.2%

Largest owners	Shares	Value	Change
Jennison Associates	19.94 mm	$1.72 tn	-1.2%
BAC Bank of America	15.49 mm	$1.33 tn	+8.1%
GQG Partners	12.99 mm	$1.12 tn	+74.7%
Fisher Asset Management	12.64 mm	$1.09 tn	-5.0%
MS Morgan Stanley	12.20 mm	$1.05 tn	-15.0%
Loomis Sayles & Co L P	11.57 mm	$995.40 mm	+34.2%
Fayez Sarofim & Co	11.38 mm	$979.29 bn	-6.8%
FMR	10.02 mm	$862.08 bn	-44.1%
Folketrygdfondet	8.90 mm	$765.92 bn	+0.5%
Renaissance Technologies	8.31 mm	$715.08 bn	+1.5%

Largest transactions	Shares	Bought/sold	Change
FMR	10.02 mm	-7.91 mm	-44.1%
GQG Partners	12.99 mm	+5.56 mm	+74.7%
RJF Raymond James Financial	4.71 mm	+4.71 mm	NEW
Raymond James & Associates	0.00	-3.53 mm	EXIT
T. Rowe Price	6.35 mm	-3.24 mm	-33.8%
Loomis Sayles & Co L P	11.57 mm	+2.95 mm	+34.2%
Nuveen Asset Management	6.24 mm	+2.64 mm	+73.2%
MS Morgan Stanley	12.20 mm	-2.16 mm	-15.0%
Two Sigma Investments	1.84 mm	+1.84 mm	NEW
International Assets Investment Management	19.91 k	-1.79 mm	-98.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

3 Stocks That Will Profit From Trump's Drug Price Cut

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.

Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains optimistic amid mixed signals.

Novo Nordisk's Ozempic Weight Loss Jabs Could Boost UK Economy By $6 Billion, Study Finds

Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing alcohol use, though high costs may limit broad access.

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

Press releases

From Benzinga Pro

Novo Nordisk A/S Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 24, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Novo Nordisk A/S ("Novo Nordisk" or the

Novo Nordisk A/S Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights – NVO

NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE:NVO) of a class action securities lawsuit. CLASS

NVO DEADLINE ALERT: Novo Nordisk (NVO) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 25th Deadline in Securities Class Action

SAN FRANCISCO, March 24, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk A/S (NYSE:NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its experimental

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.